180 related articles for article (PubMed ID: 37902013)
1. Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities.
Rodzoń-Norwicz M; Norwicz S; Sowa-Kućma M; Gala-Błądzińska A
Endokrynol Pol; 2023; 74(5):490-498. PubMed ID: 37902013
[TBL] [Abstract][Full Text] [Related]
2. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
4. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.
Ketteler M; Bover J; Mazzaferro S
Nephrol Dial Transplant; 2023 May; 38(6):1397-1404. PubMed ID: 35977397
[TBL] [Abstract][Full Text] [Related]
5. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
6. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
7. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
[TBL] [Abstract][Full Text] [Related]
8. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
Pazianas M; Miller PD
J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
[TBL] [Abstract][Full Text] [Related]
9. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
10. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
[TBL] [Abstract][Full Text] [Related]
11. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
13. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.
Bozic M; Diaz-Tocados JM; Bermudez-Lopez M; Forné C; Martinez C; Fernandez E; Valdivielso JM
Nephrol Dial Transplant; 2022 Mar; 37(4):663-672. PubMed ID: 34021359
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for secondary hyperparathyroidism.
Cozzolino M; Tomlinson J; Walsh L; Bellasi A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
16. Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.
Oltmann SC; Madkhali TM; Sippel RS; Chen H; Schneider DF
J Surg Res; 2015 Nov; 199(1):115-20. PubMed ID: 25982045
[TBL] [Abstract][Full Text] [Related]
17. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
19. Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM).
Torregrosa JV; Bover J; Rodríguez Portillo M; González Parra E; Dolores Arenas M; Caravaca F; González Casaus ML; Martín-Malo A; Navarro-González JF; Lorenzo V; Molina P; Rodríguez M; Cannata Andia J
Nefrologia (Engl Ed); 2023 Jun; 43 Suppl 1():1-36. PubMed ID: 37202281
[TBL] [Abstract][Full Text] [Related]
20. [Update 2017 of the KDIGO guidelines on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). What are the real changes?].
Pasquali M; Bellasi A; Cianciolo G; Massimetti C; Mereu MC; Morrone L; Panuccio V;
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
